Recent progress and controversies in the treatment of metastatic hormone-sensitive prostate cancer

Androgen deprivation therapy (ADT) has long been the only treatment for metastatic hormone-sensitive prostate cancer (mHSPC). In recent years, with the use of docetaxel chemotherapy and the emergence of various novel hormone therapy drugs, such as Abiraterone, Enzalutamide, Apalutamide, Darolutamide, and Rezvilutamide, the treatment strategies for mHSPC have been greatly changed. Furthermore, local treatment has been added to the treatment of low tumor burden mHSPC and triple therapy has been regarded as an important treatment choice for high tumor burden mHSPC. The survival rate of mHSPC patients has increased significantly and the quality of life also improved with these new treatment strategies. This article reviews the latest advances and controversies in the current treatment of mHSPC. Ongoing clinical trials are introduced and further directions are also discussed in this mini-review.

Metastatic hormone-sensitive prostate cancer; Novel hormone therapy; Androgen deprivation therapy; Triple therapy; Combination therapy; Prostate cancer

[1] Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. 2021; 71: 209–249.

[2] Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. The New England Journal of Medicine. 2017; 377: 352–360.

[3] Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, et al. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. The Lancet Oncology. 2019; 20: 686–700.

[4] James ND, de Bono JS, Spears MR, Clarke NW, Mason MD, Dearnaley DP, et al. Abiraterone for prostate cancer not previously treated with hormone therapy. The New England Journal of Medicine. 2017; 377: 338–351.

[5] Hoyle AP, Ali A, James ND, Cook A, Parker CC, de Bono JS, et al. Abiraterone in “high-”and “low-risk” metastatic hormone-sensitive prostate cancer. European Urology. 2019; 76: 719–728.

[6] Chi KN, Agarwal N, Bjartell A, Chung BH, Pereira de Santana Gomes AJ, Given R, et al. Apalutamide for metastatic, castration-sensitive prostate cancer. The New England Journal of Medicine. 2019; 381: 13–24.

[7] Chi KN, Chowdhury S, Bjartell A, Chung BH, Pereira de Santana Gomes AJ, Given R, et al. Apalutamide in patients with metastatic castration-sensitive prostate cancer: final survival analysis of the randomized, double-blind, Phase III TITAN Study. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2021; 39: 2294–2303.

[8] Agarwal N, McQuarrie K, Bjartell A, Chowdhury S, Pereira de Santana Gomes AJ, Chung BH, et al. Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study. The Lancet Oncology. 2019; 20: 1518–1530.

[9] Davis ID, Martin AJ, Stockler MR, Begbie S, Chi KN, Chowdhury S, et al. Enzalutamide with standard first-line therapy in metastatic prostate cancer. The New England Journal of Medicine. 2019; 381: 121–131.

[10] Armstrong AJ, Szmulewitz RZ, Petrylak DP, Holzbeierlein J, Villers A, Azad A, et al. ARCHES: a randomized, Phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. Journal of Clinical Oncology. 2019; 37: 2974–2986.

[11] Armstrong AJ, Shore ND, Szmulewitz RZ, Petrylak DP, Holzbeierlein J, Villers A, et al. Efficacy of enzalutamide plus androgen deprivation therapy in metastatic hormone-sensitive prostate cancer by pattern of metastatic spread: ARCHES post hoc analyses. Journal of Urology. 2021; 205: 1361–1371.

[12] Gu W, Han W, Luo H, Zhou F, He D, Ma L, et al. Rezvilutamide versus bicalutamide in combination with androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer (CHART): a randomized, open-label, phase 3 trial. The Lancet Oncology. 2022; 23: 1249–1260.

[13] Sweeney CJ, Chen Y, Carducci M, Liu G, Jarrard DF, Eisenberger M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. The New England Journal of Medicine. 2015; 373: 737–746.

[14] Kyriakopoulos CE, Chen YH, Carducci MA, Liu G, Jarrard DF, Hahn NM, et al. Chemohormonal therapy in metastatic hormone- sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial. Journal of Clinical Oncology. 2018; 36: 1080–1087.

[15] James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomized controlled trial. The Lancet. 2016; 387: 1163–1177.

[16] Clarke NW, Ali A, Ingleby FC, Hoyle A, Amos CL, Attard G, et al. Addition of docetaxel to hormonal therapy in low-and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial. Annals of Oncology. 2019; 30: 1992–2003.

[17] Smith MR, Hussain M, Saad F, Fizazi K, Sternberg CN, Crawford ED, et al. Darolutamide and survival in metastatic, hormone-sensitive prostate cancer. The New England Journal of Medicine. 2022; 386: 1132–1342.

[18] Fizazi K, Foulon S, Carles J, Roubaud G, McDermott R, Fléchon A, et al. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomized, phase 3 study with a 2 × 2 factorial design. The Lancet. 2022; 399: 1695–1707.

[19] Connor MJ, Shah TT, Horan G, Bevan CL, Winkler M, Ahmed HU. Cytoreductive treatment strategies for de novo metastatic prostate cancer. Nature Reviews Clinical Oncology. 2020; 17: 168–182.

[20] Boeve LMS, Hulshof M, Vis AN, Zwinderman AH, Twisk JWR, Witjes WPJ, et al. Effect on survival of androgen deprivation therapy alone compared to androgen deprivation therapy combined with concurrent radiation therapy to the prostate in patients with primary bone metastatic prostate cancer in a prospective randomized clinical trial: data from the HORRAD trial. European Urology. 2019; 75: 410–418.

[21] Parker CC, James ND, Brawley CD, Clarke NW, Hoyle AP, Ali A, et al. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomized controlled phase 3 trial. The Lancet. 2018; 392: 2353–2366.

[22] Parker CC, James ND, Brawley CD, Clarke NW, Ali A, Amos CL, et al. Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomized controlled trial. PLOS Medicine. 2022; 19: e1003998.

[23] Heidenreich A, Fossati N, Pfister D, Suardi N, Montorsi F, Shariat S, et al. Cytoreductive radical prostatectomy in men with prostate cancer and skeletal metastases. European Urology Oncology. 2018; 1: 46–53.

[24] Sooriakumaran P, Wilson C, Rombach I, Hassanali N, Aning J, D. Lamb A, et al. Feasibility and safety of radical prostatectomy for oligo‐metastatic prostate cancer: the testing radical prostatectomy in men with prostate cancer and oligo‐metastases to the bone (TRoMbone) trial. BJU International. 2022; 130: 43–53.

[25] Rahnama’i MS. Prostate cancer drug therapy: what have clinicians missed during the COVID-19 pandemic. American Journal of Men’s Health. 2022; 16: 155798832211155.

[26] Fossati N, Giannarini G, Joniau S, Sedelaar M, Sooriakumaran P, Spahn M, et al. Newly diagnosed oligometastatic prostate cancer: current controversies and future developments. European Urology Oncology. 2022; 5: 587–600.

[27] Mandel P, Hoeh B, Wenzel M, Preisser F, Tian Z, Tilki D, et al. Triplet or doublet therapy in metastatic hormone-sensitive prostate cancer patients: a systematic review and network meta-analysis. European Urology Focus. 2023; 9: 96–105.

[28] Wala J, Nguyen P, Pomerantz M. Early treatment intensification in metastatic hormone-sensitive prostate cancer. Journal of Clinical Oncology. 2023; 41: 3584–3590.

[29] Gebrael G, Fortuna GG, Sayegh N, Swami U, Agarwal N. Advances in the treatment of metastatic prostate cancer. Trends in Cancer. 2023; 9: 840–854.

[30] Cahill EM, Pfail JL, Fu MZ, Saraiya B, Mayer T, Stephenson RD, et al. Metastasis-directed therapy for oligometastatic castration-sensitive prostate cancer: an alternative to ADT? Current Urology Reports. 2023; 24: 299–306.

[31] Graefen M, Joniau S. Radical prostatectomy or radiotherapy in oligometastatic prostate cancer: is it nearly time to call it a draw? European Urology Oncology. 2022; 5: 528–529.

[32] Galgano SJ, McDonald AM, West JT, Rais-Bahrami S. Defining oligometastatic disease in the new era of PSMA-PET imaging for primary staging of prostate cancer. Cancers. 2022; 14: 3302.

[33] Gillessen S, Armstrong A, Attard G, Beer TM, Beltran H, Bjartell A, et al. Management of patients with advanced prostate cancer: report from the advanced prostate cancer consensus conference 2021. European Urology. 2022; 82: 115–141.

[34] Brighi N, Conteduca V, Lolli C, Gurioli G, Schepisi G, Palleschi M, et al. The cyclin-dependent kinases pathway as a target for prostate cancer treatment: rationale and future perspectives. Critical Reviews in Oncology/Hematology. 2021; 157: 103199.

[35] Mizuno K, Beltran H. Future directions for precision oncology in prostate cancer. The Prostate. 2022; 82: S86–S96.

[36] Jamaspishvili T, Berman DM, Ross AE, Scher HI, De Marzo AM, Squire JA, et al. Clinical implications of PTEN loss in prostate cancer. Nature Reviews Urology. 2018; 15: 222–234.

[37] Zhang N, Liu X, Qin J, Sun Y, Xiong H, Lin B, et al. LIGHT/TNFSF14 promotes CAR-T cell trafficking and cytotoxicity through reversing immunosuppressive tumor microenvironment. Molecular Therapy. 2023; 31: 2575–2590.

[39] Maselli FM, Giuliani F, Laface C, Perrone M, Melaccio A, De Santis P, et al. Immunotherapy in prostate cancer: state of art and new therapeutic perspectives. Current Oncology. 2023; 30: 5769–5794.

[40] Mohammad SR, Bach C, Schulze-hagen M, Kuhl CK, Vögeli TA. Can the predictive value of multiparametric MRI for prostate cancer be improved by a liquid biopsy with SelectMDx? Cancer Reports. 2021; 4: e1396.